New strategy aims to tame common virus after stem cell transplants
NCT ID NCT01199562
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at whether delaying or adjusting anti-CMV treatment can still keep patients safe while reducing unnecessary medication.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
153 people
The number who actually took part.
- Start date
-
Dec 2010
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis: hematologic malignancies/disorders including aplastic anemia and myelodysplastic syndrome * Procedure: first allogeneic, T cell-replete transplantation of stem-cells from peripheral blood or bone marrow of an human leukocyte antigen (HLA) matched, unrelated or nonsyngeneic sibling donor * CMV seropositive donor and/or recipient * Performance level: must have already been determined to be eligible for HCT at City of Hope (COH) * Organ function requirements: The minimum organ function requirements should be the same as the requirements for HCT * Informed Consent: All patients must be capable of signing a written informed consent and no consent can be provided by a legal guardian Exclusion Criteria: * The recipient had prior polymerase chain reaction (PCR) positive CMV infection in blood or organ-specific disease in the past 12 months * The source of hematopoietic stem cells is T-cell depleted * Concomitant anti-graft-versus-host disease (GVD) treatment includes in vivo T cell depletion * Recipient is human immunodeficiency virus (HIV)-1 positive * No prior allogeneic HCT (Allo HCT) (autologous HCT \[Auto HCT\] is allowed)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Accelerated phase chronic myelogenous leukemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a p53-Targeting drug boost chemotherapy in Hard-to-Treat blood cancers?
- Can adding venetoclax make donor stem cell transplants safer for High-Risk blood cancers?
- Can adding linperlisib to standard chemotherapy improve outcomes in rare T-Cell lymphoma?
- Half-Matched stem cells tested as a cure for severe aplastic anemia
- Tweaking donor cells may shield older transplant patients from a dangerous complication
- Pens and vouchers: can small rewards boost participation in blood cancer research?